Epidemiologic Relationships Between A1C and All-Cause Mortality During a Median 3.4-Year Follow-up of Glycemic Treatment in the ACCORD Trial
Open accessThe DOI matches its Crossref record; 20 of the 21 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Randomized treatment comparing an intensive glycemic treatment strategy with a standard strategy in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial was ended early because of an unexpected excess of mortality in the intensive arm. As part of ongoing post hoc analyses of potential mechanisms for this finding, we explored whether on-treatment A1C itself had an independent relationship with mortality. RESEARCH DESIGN AND METHODS: Participants with type 2 diabetes (n = 10,251 with mean age 62 years, median duration of diabetes 10 years, and median A1C 8.1%) were randomly assigned to treatment strategies targeting either A1C <6.0% (intensive) or A1C 7.0–7.9% (standard). Data obtained during 3.4 (median) years of follow-up before cessation of intensive treatment were analyzed using several multivariable models. RESULTS: Various characteristics of the participants and the study sites at baseline had significant associations with the risk of mortality. Before and after adjustment for these covariates, a higher average on-treatment A1C was a stronger predictor of mortality than the A1C for the last interval of follow-up or the decrease of A1C in the first year. Higher average A1C was associated with greater risk of death. The risk of death with the intensive strategy increased approximately linearly from 6–9% A1C and appeared to be greater with the intensive than with the standard strategy only when average A1C was >7%. CONCLUSIONS: These analyses implicate factors associated with persisting higher A1C levels, rather than low A1C per se, as likely contributors to the increased mortality risk associated with the intensive glycemic treatment strategy in ACCORD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The potential risks of intensive glycemic control may be obviated by incorporating agents that are not associated with hypoglycemia, especially in persons with frequent severe hypoglycemia, hypoglycemia unawareness, or a very long duration of DM, and particularly in the presence of established and advanced atherosclerosis, advanced age, and terminal illness.69,70,76–81”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [80]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A corollary of this issue is the safety of those therapies in view of the demonstrated increase of frequency of severe hypoglycemia during attempts at intensive glycemic control.70,76,80,85,86”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [80]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“These trials have more or less uniformly demonstrated a benefit, with lifestyle more efficacious than all medications with the exception of the thiazolidinediones140–152.”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [148]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059 · cited 1×
“This association, not taking into consideration the glycemic treatment strategy, is similar to the 12 and 14% increments of mortality associated with 1% higher average A1C in epidemiologic analyses from other studies (6,19).”
ResultEffects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
Stamler, J., Vaccaro, O., Neaton, J. D., Wentworth, D., & The Multiple Risk Factor Intervention Trial Research Group (1993) · Diabetes Care · doi:10.2337/diacare.16.2.434 · Cited by 4,063
Flexible smoothing with B-splines and penalties
Eilers, P. H. C., & Marx, B. D. (1996) · Statistical Science · doi:10.1214/ss/1038425655 · Cited by 3,666 · cited 1×
“Curves modeling the relationships over the range of observed A1C values (penalized B-splines) (17,18) were used to explore the linearity assumption in the Cox proportional hazards model.”
MethodDiabetes and Cardiovascular Disease: The Framingham Study
Kannel, W. B. (1979) · JAMA · doi:10.1001/jama.1979.03290450033020 · Cited by 2,936
Coutinho, M., Gerstein, H. C., Wang, Y., & Yusuf, S. (1999) · Diabetes Care · doi:10.2337/diacare.22.2.233 · Cited by 1,685
Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus
Selvin, E., Marinopoulos, S., Berkenblit, G., Rami, T., Brancati, F. L., Powe, N. R., & Golden, S. H. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-6-200409210-00007 · Cited by 1,657
Hurvich, C. M., Simonoff, J. S., & Tsai, C.-L. (1998) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/1467-9868.00125 · Cited by 1,241 · cited 1×
“Curves modeling the relationships over the range of observed A1C values (penalized B-splines) (17,18) were used to explore the linearity assumption in the Cox proportional hazards model.”
MethodSkyler, J. S., Bergenstal, R., Bonow, R. O., Buse, J., Deedwania, P., Gale, E. A. M., Howard, B. V., Kirkman, M. S., Kosiborod, M., Reaven, P., et al. (2009) · Diabetes Care · doi:10.2337/dc08-9026 · Cited by 881
Self-citation
Cited by
Items 301–400 of 404
For debate; pharmacological priorities in advanced type 2 diabetes
Hodish, I. (2019) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2019.107510 · Cited by 4
Glycemic Control: A Combination of Lifestyle Management and the Use of Drugs
Standl, E., Erbach, M., & Schnell, O. (2012) · Cardiology and Therapy · doi:10.1007/s40119-012-0007-7 · Cited by 5
“It should be emphasized, however, that although the metformin UKPDS subgroup study looked encouraging, the results on reducing hard CV outcomes, including mortality, have never been confirmed in independent randomized trials, but only in huge observational data bases [27, 29].”
ResultCardiovascular Disease and Glycemic Treatment
Bloomgarden, Z. T. (2010) · Diabetes Care · doi:10.2337/dc10-zb11 · Cited by 4
Tanaka, N., & Hiura, Y. (2015) · Endocrine Journal · doi:10.1507/endocrj.ej14-0610 · Cited by 4
Can the current healthcare delivery model cope with advanced type 2 diabetes?
Hodish, I. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.01.005 · Cited by 4
“Those studies also did not show that low A1C per se or insulin therapy was the cause for poor outcomes (Riddle et al., 2010).”
BackgroundGriffin, S. (2012) · Annals of Medicine · doi:10.3109/07853890.2012.679959 · Cited by 4
“Multiple studies have shown that episodes of hypoglycemia may be associated with increased cardiovascular risk (14,15), although other studies have produced data that confl ict with these reports (16,17).”
BackgroundHeng, X.-P., Yang, L., Chen, M., Li, L., Huang, S.-P., & Lei, Y. (2015) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-015-0780-5 · Cited by 4
Glycemia and cardiovascular diseases in type 2 diabetes
Skyler, J. S. (2010) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2010.02276.x · Cited by 4
Lower A1c Targets in Type 2 Diabetes and Increased Mortality: Causal or Casual?
Garber, A. J., Newcomer, J. W., & Hennekens, C. H. (2013) · The American Journal of Medicine · doi:10.1016/j.amjmed.2013.04.014 · Cited by 4
Bilous, F. R., Donnelly, R., & Iskandar Idris DM, F. (2021) · Wiley eBooks · doi:10.1002/9781118976074.ch10 · Cited by 4
Landau, J., Tiram, Y., & Ilan, Y. (2025) · Biomedicines · doi:10.3390/biomedicines13112645 · Cited by 4
“Paradoxically, the heightened risk was more significant among participants with higher mean HbA1c levels and those who showed slower reductions in HbA1c [94].”
Comprehensive diabetes cardiovascular treatment = sugar + blood pressure + lipids
Bloomgarden, Z. T., Handelsman, Y., & EINHORN, D. F. (2011) · Journal of Diabetes · doi:10.1111/j.1753-0407.2011.00161.x · Cited by 3
“In fact, there was a significant reduction of nearly 10-fold in mortality among the intensive treatment group at an A1c level of 6% and a 10-fold increase in mortality in those who were randomized to intensive treatment but had an A1c of 9%.(9) This actually implies that intensive control of glucose, in a manner that…”
BackgroundManagement of Type 2 Diabetes Mellitus in the Very Elderly: One Practice’s Experience
Grajower, M. M., & LeRoith, D. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.03.271 · Cited by 3
Liu, I. H., Uchida, Y., Joo, E., Mano-Usui, F., Okura, M., Chishima, Y., Ikeda, K., & Inagaki, N. (2023) · Japanese Psychological Research · doi:10.1111/jpr.12464 · Cited by 3
Murayama, H., Toda, M., Tsumiyama, I., Shinfuku, Y., Taniguchi, T., Tanaka, Y., & Oyama, N. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1585802 · Cited by 3
Clinical experience with liraglutide
Bain, S. C., & McKenna, J. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02494.x · Cited by 3
Beneficial and Detrimental Effects of Glycemic Control on Cardiovascular Disease in Type 2 Diabetes
Taub, P. R., Higginbotham, E., & Henry, R. R. (2013) · Current Cardiology Reports · doi:10.1007/s11886-012-0332-4 · Cited by 3
Objectifs du contrôle de la glycémie
Imran, S. A., RABASA-LHORET, R. P. R., & Ross, S. A. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.07.036 · Cited by 4
Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes
Schinner, S. (2011) · Yearbook of Medicine · doi:10.1016/s0084-3873(11)00369-5 · Cited by 3
Rashid, F., Abdelgadir, E., Alsaeed, M., Alemadi, B., Khalifa, A. A., Farooqi, M. H., Alawadi, F., & Bashier, A. M. (2018) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2018.11.013 · Cited by 3
Min, J. Y., Hackstadt, A. J., Griffin, M. R., Greevy, R. A., Chipman, J., Grijalva, C. G., Hung, A. M., & Roumie, C. L. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13846 · Cited by 3
The Avandia debate: An unhappy conclusion
Bloomgarden, Z. T., & Handelsman, Y. (2010) · Journal of Diabetes · doi:10.1111/j.1753-0407.2010.00096.x · Cited by 3
Improvements in Our Understanding of Diabetes Mellitus
Hirsch, I. B. (2013) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.07.011 · Cited by 3
Bloomgarden, Z. T., & Handelsman, Y. (2014) · Journal of Diabetes · doi:10.1111/1753-0407.12152 · Cited by 3
Is glycemic control a quinidine‐like intervention? 控制血糖与使用奎尼丁治疗一样吗?
Bloomgarden, Z. T. (2014) · Journal of Diabetes · doi:10.1111/1753-0407.12170 · Cited by 3
“in the glycemic intervention arm those patients attaining HbA1c levels <7% had an actual reduction in mortality.(7) This is perhaps predictable from the finding that there”
BackgroundGlycemic control and the heart: it matters how you get there
Bloomgarden, Z. T. (2016) · Journal of Diabetes · doi:10.1111/1753-0407.12398 · Cited by 3
Tarricone, A. N., Coye, T. L., Gee, A., Najafi, B., Siah, M. C., & Lavery, L. A. (2025) · International Wound Journal · doi:10.1111/iwj.70122 · Cited by 2
“17 However, CKD obscures this relationship.”
Controlling glucose levels in elderly people—benefits versus risks
Riddle, M. C. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.23 · Cited by 2
Self-citationInsulin resistance: Unsolved issues of harm and use
Belik, E. V., & Gruzdeva, O. V. (2020) · Сибирский журнал клинической и экспериментальной медицины · doi:10.29001/2073-8552-2019-34-4-39-48 · Cited by 3
Severe hypoglycemia and cardiovascular disease
Tak, S., & Jain, A. (2022) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2022.100357 · Cited by 2
Ooi, S.-W., Yeh, S., Chang, Y., Li, C., & Chen, H.-F. (2023) · PLoS ONE · doi:10.1371/journal.pone.0288360 · Cited by 3
“Moreover, participants who continued to have an average HbA1c >7% in the ACCORD study seemed to be at greater risk of mortality than those with an average HbA1c <7% [26].”
BackgroundTarricone, A. N., Gee, A., Boulton, A. J. M., Rogers, L. C., & Lavery, L. A. (2024) · Annals of Vascular Surgery · doi:10.1016/j.avsg.2024.12.057 · Cited by 2
Translating “Nondiabetic” A1C Levels to Clinical Practice
Cefalu, W. T. (2010) · Diabetes · doi:10.2337/db10-0800 · Cited by 2
Hypoglycemic Morbidity and Mortality in Diabetes
Son, J. W. (2016) · Journal of Korean Diabetes · doi:10.4093/jkd.2016.17.1.17 · Cited by 2
Wayne, N., Cercone, N. J., Li, J., Zohar, A., Katz, J. D., Brown, P., & Ritvo, P. (2016) · JMIR Diabetes · doi:10.2196/diabetes.4506 · Cited by 2
“Diabetes is a cluster of metabolic conditions characterized by dysglycemia from defects in insulin secretion and/or unhealthy behaviors that cause debilitating complications and death [1,2].”
BackgroundZhang, X., Nie, M., Chen, X., Liang, Z., & Zhao, Q. (2021) · Journal of Interventional Cardiology · doi:10.1155/2021/5565987 · Cited by 3
“Three studies, including ADVANCE, ACCORD and VADT, showed that hypoglycemia was associated with higher mortality rates than standard glycemic levels (25).”
BackgroundRationale for glycemic control to improve cardiovascular outcome: Lessons from east and west
Bloomgarden, Z. T., & Chan, J. C. N. (2021) · Journal of Diabetes · doi:10.1111/1753-0407.13204 · Cited by 2
“In the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial where higher mortality rates were reported with intensive glycemic treatment, the increase in mortality occurred only in participants with higher baseline HbA1c(13) or higher mean on-trial HbA1c.(14) Taken together, these trials' evidence suggeste…”
BackgroundPerera, P., O’Donnabhain, R., Fazio, T. N., Johnson, D. F., & Lange, P. (2022) · Clinical Medicine Insights Cardiology · doi:10.1177/11795468221133607 · Cited by 2
Wang, N., Zoungas, S., & Chalmers, J. P. (2022) · La Presse Médicale · doi:10.1016/j.lpm.2022.104160 · Cited by 3
WITHDRAWN: Targets for Glycemic Control
Imran, S. A., RABASA-LHORET, R. P. R., & Ross, S. A. (2016) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2016.04.008 · Cited by 4
RetractedBailey, C. J., & Krentz, A. J. (2016) · Wiley eBooks · doi:10.1002/9781118924853.ch31 · Cited by 2
Shao, H., Laxy, M., Gregg, E. W., Albright, A. L., & Zhang, P. (2020) · Value in Health · doi:10.1016/j.jval.2020.09.010 · Cited by 1
Challenges and Management Strategies in the Nutrition of Older People with Diabetes
Farooqui, K. J., Khan, A. A., Paul, T., Sirajudeen, J., Khan, H. A., Farooqui, F. K., Ferih, K. R., Al-Yahary, H. H., Haider, F., & Elzouki, A.-N. Y. (2023) · Journal of Diabetes and Endocrine Practice · doi:10.1055/s-0043-1771201 · Cited by 2
All-cause mortality among primary care patients with type 2 diabetes: a prospective cohort study
Enguix, D. M., Rodríguez, J. C. A., Rodríguez, A. H., Cambronero, M. S., Torres, M. N. G., Cárdenas, M. G., Bravo, A. G., Lavie, C. J., & Amaro‐Gahete, F. J. (2025) · Postgraduate Medicine · doi:10.1080/00325481.2025.2510709 · Cited by 1
“Our data demonstrates that those patients with extremely low and high HbA1c may be associated with an increased mortality risk, emphasizing the intricate relationship between HbA1c control and mortality in T2D patients, as reported in previous studies [26,27].”
Making sense of outcomes in the ACCORD trial
White, A., & Fisher, M. (2011) · Practical Diabetes · doi:10.1002/pdi.1567 · Cited by 1
Consoli, A. (2010) · Giornale italiano di cardiologia · doi:10.1714/565.6704 · Cited by 1
Hailpern, S. M., Santel, F., Mazurek, J. A., Ramirez, S., Remick, J. D., Klein, J., Schubart, U. K., & Nordin, C. (2014) · Cardiovascular Endocrinology · doi:10.1097/xce.0000000000000033 · Cited by 1
Aslan, O., Yaylalı, Y. T., Yurtdaş, M., Yaylalı, G. F., Aybek, H., & YILDIRIM, S. (2021) · Phoenix Medical Journal · doi:10.38175/phnx.885133 · Cited by 1
Alanazi, F. K., Almofarh, A. A., Alzahrani, I. A., AlFahid, F. A., alhamdi, M. H., Alfaifi, M. G. Y., Alanazi, F. R. R., khaledalshehri, A., & Alharbi, H. A. (2023) · International Journal of Engineering Applied Sciences and Technology · doi:10.33564/ijeast.2023.v08i03.006 · Cited by 1
Colley, J., Hughes, S. F., Dambha‐Miller, H., & Price, H. C. (2024) · Diabetic Medicine · doi:10.1111/dme.15445 · Cited by 2
Medical management of diabetic retinopathy
Thomsen, S., Welch, R. J., & Diana, V. (2015) · Springer eBooks · doi:10.1007/978-3-319-08329-2_4 · Cited by 1
Hao, Y.-D., Hao, P., Wang, Z., Zhao, Y., Zhou, Z., Liu, Y., Jia, D., Han, H., Hu, B., Shen, H., et al. (2020) · PubMed Central · doi:10.11909/j.issn.1671-5411.2020.09.004 · Cited by 1
Vascular Complications in Type 2 Diabetes
Chen-Ku, C. H. (2020) · Springer eBooks · doi:10.1007/978-3-030-53370-0_37 · Cited by 1
Yudkin, J. S., Richter, B., & Gale, E. A. M. (2010) · Diabetologia · doi:10.1007/s00125-010-2016-1 · Cited by 1
Hemoglobin A1c Targets for Glycemic Control With Pharmacologic Therapy
Zonszein, J., & Brownlee, M. (2018) · Annals of Internal Medicine · doi:10.7326/l18-0372 · Cited by 1
Ipp, E., & Kumar, M. (2022) · Diabetes Care · doi:10.2337/dci21-0053 · Cited by 1
Edward, J. A., Josey, K., Bahn, G., Caplan, L., Reusch, J. E. B., Reaven, P. D., Ghosh, D., & Raghavan, S. (2022) · Research Square · doi:10.21203/rs.3.rs-1439428/v1 · Cited by 1
Bailey, C. J., & Krentz, A. J. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch35 · Cited by 2
Almokayyad, R. M., & Cuddihy, R. M. (2021) · Wiley eBooks · doi:10.1002/9781119603207.ch7
Potential for Poor Wound Healing
Fischer, D. J., Treister, N. S., & Pinto, A. (2013) · doi:10.1002/9781118783283.ch5
Glycemia and CVD and Its Management
Stephens, J. W., Mallipedhi, A., & Bain, S. C. (2014) · Wiley eBooks · doi:10.1002/9781118337967.ch5
Prescribing antidiabetic drugs for patients with renal dysfunction
Wilding, J. P. H., Kirby, M. G., & Evans, M. (2011) · Prescriber · doi:10.1002/psb.815
Zoungas, S., Chalmers, J. P., Li, Q., & Woodward, M. (2012) · Diabetologia · doi:10.1007/s00125-012-2576-3
Intensification of polypharmacy glucose-lowering treatment in type-2 diabetes: When to be cautious?
Charbonnel, B. H. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.05.008
Bloomgarden, Z. T. (2012) · Journal of Diabetes · doi:10.1111/j.1753-0407.2012.00228.x · Cited by 1
Exenatide: Review of its Role as Adjunctive Therapy in Patients with Type 2 Diabetes
Bellows, O. K., Hunter, E. L., & McAdam-Marx, C. (2011) · Clinical Medicine Reviews in Vascular Health · doi:10.4137/cmrvh.s1664 · Cited by 1
V-shaped relationship between HbA1c and all-cause mortality in the elderly with type 2 diabetes
Funase, Y., Fumisawa, Y., Yamada, M., Nishimura, R., Oike, Y., Toba, K., Yazaki, Y., Yokoyama, T., Suzuki, N., Seki, K., et al. (2014) · European Geriatric Medicine · doi:10.1016/j.eurger.2014.07.012
Lim, S. K., & Rutter, M. K. (2011) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-011-0208-y
“The ACCORD trial was not designed to determine the mechanisms of effects, and despite much speculation [7–9], the cause of the increased mortality remains unclear.”
Czupryniak, L., Szymańska‐Garbacz, E., Pawłowski, M., Saryusz‐Wolska, M., & Loba, J. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01372.x
“The analyses of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study published in 2010 [2], the data available from the Veteran Affairs Diabetes Trial (VADT) [3] and the meta-analysis by Turnbull et al.”
Optimizing Care in Diabetes: a Quixotic Challenge
Friedman, E. A. (2012) · Diabetes Care · doi:10.2337/dc12-0345
Ross, S. A., Tildesley, H. D., & Ashkenas, J. (2011)
3. Glycemic Management of Type 2 Diabetes
D’Alessio, D. A., & Hirsch, I. B. (2011) · Translational endocrinology & metabolism · doi:10.1210/team.9781879225824.ch3
Rothschild, S. K., Martin, M. A., Swider, S. M., Lynas, C. M. T., Janssen, İ., Avery, E., & Powell, L. H. (2014)
Krempf, M., & Charbonnel, B. H. (2015) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(15)30263-7
Diagnosi di diabete: è sufficiente l'HbA1c?
Cosma, C. (2013) · Padua Research Archive (University of Padova)
Optimierung der glykämischen Kontrolle und des kardiovaskulären Risikos
Siegmund, T., & Zelihic, E. (2015) · CardioVasc · doi:10.1007/s15027-015-0640-x
“Die eingehende Prüfung der Daten zeigte, dass die meisten Todesfälle in einer Untergruppe auraten, deren HbA1c-Werte trotz intensiver Bemühungen nicht verbessert werden konnten, während die geringste Mortalität bei den Patienten mit den besten HbA1c-Werten (< 7 %) zu verzeichnen war [9].”
BackgroundWatada, H. (2013) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.102.902
Dose d’insuline et mortalité cardiovasculaire : nouvelles données de l’étude ACCORD
Mohammedi, K. (2016) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(16)30079-7
Diabetes and Cardiovascular Disease
Gore, M. O., Inzucchi, S. E., & McGuire, D. K. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-1366-4.00021-4
Venkataraman, K., Kao, S. L., Thai, A. C., Salim, A., Heng, D., & Khoo, E. Y. H. (2012)
Development of Cardiovascular Risk Assessment Model for People with Type 2 Diabetes in Oman
Alrawahi, A. H. (2017) · Griffith Research Online · doi:10.25904/1912/3256
Glycemic Targets and Prevention of Chronic Complications
Cernea, S., Cahn, A., & Raz, I. (2018) · Endocrinology · doi:10.1007/978-3-319-27317-4_14-1
Insulin Therapy and Cardiovascular Outcome Trials (Cvots): Any Harm, Anytime?
Anyanwagu, U. (2018) · Gastroenterology Medicine & Research · doi:10.31031/gmr.2018.01.000513
“Also, unlike in the standard care arm, 1% increase in HbA1c in the intensive therapy arm was associated with a 66% greater risk of mortality thereby suggesting that factors which are associated with the persistence of high HbA1c may have driven the excess mortality seen in this arm [14].”
BackgroundFocus on Incretin-Based Therapies for Patients with Type 2 Diabetes and Cardiovascular Disease
Garber, A. J. (2011) · Endocrine Practice · doi:10.1016/s1530-891x(20)43147-7
Conget, I., Aronson, R., Lee, S., Cohen, O., & Reznik, Y. (2014) · Diabetes Care · doi:10.2337/dc14-1632 · Cited by 1
“This represents an additional therapeutic opportunity to address the unmet challenge of treating patients who are failing MDI and have a high-risk profile similar to participants in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial (3,4).”
BackgroundIndividualisierte Behandlung: Jeder Diabetiker hat sein persönliches Therapieziel
Nauck, M. A. (2015) · Deutsches Ärzteblatt · doi:10.3238/persdia.2015.04.24.04
(2011) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3283457c7d
Glycemic Targets and Prevention of Chronic Complications
Cernea, S., Cahn, A., & Raz, I. (2018) · Endocrinology · doi:10.1007/978-3-319-45015-5_14
Current literature in diabetes
(2010) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1027
Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes
Schinner, S. (2011) · Yearbook of Endocrinology · doi:10.1016/j.yend.2011.06.008
The Evaluation of Cardiovascular Risk in Diabetic Patients
Kosírová, S., Rubintova, D., Lacka, J., Klimas, J., Foltánová, T., & Tůmová, I. (2022) · European Pharmaceutical Journal · doi:10.2478/afpuc-2022-0001
Control of Blood Glucose and Cardiovascular Risk Profile
Ciardullo, S., & Perseghin, G. (2022) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-031-13009-0_28
Heart Failure and Cardiac Dysfunction in Diabetes
Afari, M. E., & Givertz, M. M. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_27
Biomathematical Analysis on Impedance Measurement During COVID-19 Pandemic
Zhao, B. (2022) · American Journal of Biomedical Science & Research · doi:10.34297/ajbsr.2022.17.002360
Oba, S., Murakami, H., Saitoh, T., Hayashi, K., Okada, Y., Imano, Y., Takaki, O., Kiryu, I., Ishikawa, M., & Sato, Y. (2024) · Asia Pacific Journal of Public Health · doi:10.1177/10105395241262852
Metadata
- Authors
- Riddle, M. C., Ambrosius, W. T., Brillon, D. J., Buse, J. B., Byington, R. P., Cohen, R. M., Goff, D. C., Malozowski, S., Margolis, K. L., Probstfield, J. L., Schnall, A., Seaquist, E. R., & for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Investigators
- Affiliations
- Oregon Health & Science University (US)
- Wake Forest University Health Sciences (US)
- Cornell University (US)
- University of North Carolina at Chapel Hill (US)
- University of Cincinnati (US)
- National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland;
- HealthPartners (US)
- University of Washington (US)
- Case Western Reserve University (US)
- University of Minnesota (US)
- Corresponding author
- Riddle, Matthew C.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2010-05-01
- Volume
- 33
- Issue
- 5
- Pages
- 983-990
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2858202
- OpenAlex
- W2078241682
- Cited by
- 406
- References
- 21
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 9 · 2023: 12 · 2022: 13 · 2021: 13 · 2020: 18 · 2019: 25 · 2018: 26 · 2017: 31 · 2016: 27 · 2015: 37 · 2014: 28 · 2013: 30 · 2012: 40
- FWCI
- 38.36
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- National Institutes of Health (n01hc95183-23-0-0, n01hc95180-24-0-1, n01hc95184-24-0-1, n01hc95181-23-0-1, n01hc95182-23-0-1, n01hc95178-28-0-1, n01hc95179-25-0-0)
- National Heart, Lung, and Blood Institute (N01- HC-95181, N01 HC095184, N01-HC- 95180, N01-HC-95178, N01 HC095182, N01 HC095181, Y01 HC001010, N01-HC-095183, N01 HC095178, N01-HC-95184, N01HC95179, IAAY1-HC-1010, IAA #Y1-HC-9035, N01 HC095180, Y01 HC009035, N01‐HC‐95183, N01-HC-95182, N01 HC095179)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- HbA1c, all-cause mortality, tight glycemic control, type 2 diabetes, ACCORD trial, mortality risk
- MeSH terms
- Aged, Cause of Death, Diabetes Mellitus, Type 2, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Hyperglycemia, Hypoglycemic Agents, Male, Middle Aged, Risk Factors, Multivariate Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.